메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

NUHS SPEARHEADS AI-POWERED BRAIN CARE PROGRAMME TO TACKLE UNDERDIAGNOSIS AND IMPROVE PREVENTION OF DEMENTIA

Novel initiative in Asia integrates predictive AI with personalised health coaching to empower early action and prevention SINGAPORE, Aug. 27, 2025 -- Dementia remains a hidden epidemic in Singapore, with slightly more than half of all cases going undiagnosed. According to the Well-being of the Singapore Elderly (WiSE) 2023[1] study, 51.5 per cent of dementia cases remain undetected. This is a troubling figure given that an estimated 45 per cent of dementia cases are preventable through early lifestyle interventions[2]. In an effort to close this gap, a multidisc
- 김갑성 기자
- 2025-08-27 21:00
NYSE Content Advisory: Pre-Market update + Wall Street braces for Nvidia's earnings

NEW YORK, Aug. 27, 2025 -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content Advisory: Pre-Market update + Wall Street braces for Nvidia’s earnings Ashley Mastronardi delivers the pre-market update on August 27th Equities are up this morning as investors wait for chip giant Nvidia's Q2 earnings report. The company is set to release the earnings after market close this afternoon. As the most heavily weig
- 황정호 기자
- 2025-08-27 20:55
Fosun International: Total Revenue for the First Half of 2025 Reaches RMB87.28 Billion, Industrial Operation Profit Amounts to RMB3.15 Billion

HONG KONG, Aug. 27, 2025 -- On 27 August, Fosun International Limited (HKEX stock code: 00656) announced its interim results for the six months ended 30 June 2025. In the first half of 2025, Fosun actively captured macroeconomic trends, maintained a clear strategic focus, and leveraged its strong capabilities in innovation and globalization to drive steady business development. During the Reporting Period, the Group's total revenue reached RMB87.28 billion, industrial operation profit amounted to RMB3.15 billion, and profit attributable to owners of the parent reached RMB661.2 million.
- 황정호 기자
- 2025-08-27 20:40
Actinogen trial using intended commercial Xanamem tablet formulation confirms target exposures in fed and fasted states

Phase 2b/3 Alzheimer's trial enrolment passes 50% - twenty US trial sites continuing to recruit participants SYDNEY, Aug. 27, 2025 -- Actinogen Medical Limited (ASX: ACW) announces that a recent trial designed to confirm therapeutic blood levels of the intended commercial tablet formulation of Xanamem®, given both with and without food, demonstrated the expected blood levels or "exposure", comparable with prior studies of a capsule formulation. This indicates that 10 mg once daily remains the target therapeutic dose for the clinical program.
- 김갑성 기자
- 2025-08-27 20:00
Innovent Announces 2025 Interim Results and Business Updates

[ 메디채널 김갑성 기자 ] Robust revenue growth and substantial profit improvement Continued exceptional executions under a clear roadmap of dual-driven growth and global innovation SAN FRANCISCO and SUZHOU, China, Aug. 27, 2025 -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces its 2025 interim results and major business updates. Dr. Michael Yu, Found
- 김갑성 기자
- 2025-08-27 18:08
Keymed Biosciences (02162.HK) Reports Strong Interim 2025 Results with Accelerated Commercialization and Robust R&D Momentum

CHENGDU, China, Aug. 27, 2025 -- Keymed Biosciences Inc. ("Keymed", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&D progress. Financially, the company achieved record revenue, driven by the strong performance of its core product, Stapokibart, an IL-4Rα antibody marketed as Kang Yue Da®. The drug generated net sales of approximately RMB 170 million. Keymed strengthened its balance sheet with a successful placement raising ~HK$864 million, providing ample funds for pipeline development and commercialization.
- 김갑성 기자
- 2025-08-27 14:02
Digital twin technology with AI to boost efficiency and reliability in pharmaceutical manufacturing

Cambridge Advanced Research and Education in Singapore (CARES), the University of Cambridge's first overseas research centre, together with the A*STAR Institute for Infocomm Research (A*STAR I2R) has developed a digital twin platform that uses artificial intelligence (AI) and real-time plant data to enhance fault detection, system monitoring, and predictive maintenance in pharmaceutical manufacturing. The technology will be commercialised through Chemical Data Intelligence, a CARES spin-off, and will be made available to the Pharma Innovation Programme Singapore (PIPS) Consortium.
- 김갑성 기자
- 2025-08-27 13:00
Crescom to Showcase Musculoskeletal AI Innovations at 26th Asian Musculoskeletal Society Annual Meeting

[ 메디채널 김갑성 기자 ] Company to present MediAI solution suite and strengthen partnerships for expansion across Southeast and East Asia SEOUL, South Korea, Aug. 27, 2025 -- Crescom, a leader in AI-powered musculoskeletal (MSK) image analysis software, announced its participation in the 26th Asian Musculoskeletal Society (AMS) Annual Meeting which takes place from August 29 through 31 at Singapore EXPO. At the event, Crescom will host an exhibition booth to showcase its AI solution suite and engage directly with healthcare professionals across the region. The company aims to
- 김갑성 기자
- 2025-08-27 09:00
TheChallenge.org: New Study by Finds Reducing Phone Use is Over Twice as Hard as Enduring a Daily Ice Bath

WARSAW, Poland, Aug. 27, 2025 -- A new social study involving 9,150 participants from 47 countries has revealed a startling modern truth: most people find it significantly harder to reduce their screen time than to plunge into a barrel of ice water every day. The study, conducted by the health and wellness project TheChallenge.org, centered on its 31-Day "Digital Detox Challenge." Participants committed to simple rules like two screen-free hours daily and a 30-minute social media cap. Despite the profound benefits reported by those who completed it, the challenge had
- 김갑성 기자
- 2025-08-27 03:37
세레신, 영국 국립보건의료연구원(NIHR) 뇌 건강 헬스테크 연구센터(HRC) 산업 파트너로 합류

덴버, 2025년 8월 27일 -- 신경대사 분야를 선도하는 글로벌 바이오텍 기업 세레신이 영국의 국립보건의료연구원(NIHR) 뇌 건강 헬스테크 연구센터 (HRC)와 파트너십을 체결했습니다. 이번 협력으로 세레신은 GE 헬스케어, 노보 노디스크, 로슈 다이애그노스틱스, 그리고 윌마 인터내셔널 산하의 캄텍 이노베이션 등 업계를 선도하는 세계적인 기업들과 함께 HRC의 일원이 되었습니다. 영국 킹스칼리지 런던(King's College London)과 사우스 런던 앤 모즐리 NHS 재단 (South London and Maudsley NHS Foundation Trust)에 기반을 둔 NIHR 헬스테크 연구센터(HRC)는 선진 기술을 바탕으로 활용하여 치매 진단, 돌봄 및 치료의 발전에 집중하는 연구기관입니다. 본 센터는 뇌 스캔, 혈액 채취, 컴퓨터를 이용한 검사 및 디지털 도구를 활용하여 치매를 보다 효과적이고 조기에 진단하는 방법을 개발할 예정이며, 이를 통해 치매가 사회 전반에 미치는 영향을 완화하는 것을 목표로 합니다. HRC는 킹스칼리지 런던 산하 정신의학, 심리학 및 신경과학 연구소
- 김갑성 기자
- 2025-08-27 00:13

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-08-30_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 08월 30일 17시 20분